The present invention is directed to multivalent DR5 binding molecules comprising one or more binding domains of anti-DR5 antibodies, in particular one or more binding domains of anti-human DR5 antibodies. The DR5 binding molecules of the present invention include bivalent and tetravalent molecules having two, three or four DR5 binding domains, each of which can bind to human DR5. In particular, the present invention is directed to multivalent DR5 binding molecules, including diabodies, and more particularly diabodies comprising a covalent complex of two or more polypeptide chains. The invention particularly relates to the multivalent DR5 binding molecule comprising the anti-DR5 antibody DR5 mAb 1 and / or DR5 mAb 2, and / or fragments of humanized and chimeric versions of the antibody. [Selection] Figure 13本発明は、抗ＤＲ５抗体の１つ又は複数の結合ドメイン、特に抗ヒトＤＲ５抗体の１つ又は複数の結合ドメインを含む、多価ＤＲ５結合分子を対象とする。本発明のＤＲ５結合分子は、２つ、３つ又は４つのＤＲ５結合ドメインを有する２価及び４価分子を含み、上記ＤＲ５結合ドメインはそれぞれ、ヒトＤＲ５に結合できる。特に本発明は、ダイアボディ、より詳細には２つ以上のポリペプチド鎖の共有結合複合体を含むダイアボディを含む、多価ＤＲ５結合分子を対象とする。本発明は特に、抗ＤＲ５抗体ＤＲ５ ｍＡｂ １及び／若しくはＤＲ５ ｍＡｂ ２、並びに／又は上記抗体のヒト化及びキメラバージョンの断片を含む、上記多価ＤＲ５結合分子に関係する。【選択図】図１３
